

Blast email about PAR-20-074 for NCI grantees (October 2020)



NATIONAL CANCER INSTITUTE

Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI R01 research projects. The applicants should propose projects that are expected to accelerate the pace of translation of NCI-supported methods/assays/technologies (referred to as "assays") to the clinic. Specifically, the focus of applications submitted in response to this FOA should be on the adaption and clinical validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") for cancer detection, diagnosis, prognosis, monitoring, and prediction of response in treatment, as well as markers for cancer prevention and control. Applications may support the acquisition of well-annotated specimens from NCI-supported or other clinical trials or observational cohorts/consortia for the purpose of clinical validation of the assay. Research projects proposed in response to this FOA encourage multi-disciplinary interaction among scientific investigators, assay developers, clinicians, statisticians, and clinical laboratory staff. Clinical laboratory scientist(s) and statistical experts are highly encouraged to comprise integral parts of the application. This FOA is not intended to support early-stage development of technology or the conduct of clinical trials, but rather the adaption and validation of assays to the point where they could be integrated into clinical trials as investigational assays/tools/devices.

Reissue of PAR-17-003; Posted date: December 10, 2019.

Expiration Date: October 29, 2022.

Application Due dates: February 28, 2020; July 10, 2020; October 27, 2020; February 26, 2021; July 13, 2021; October 26, 2021; February 28, 2022; July 11, 2022; October 28, 2022, by 5 pm local time of applicant organization.

Contact: Dr. Tracy Lively, 240-276-5944, livelyt@mail.nih.gov